Clinical Report: Exploring Weight Rebound Following Discontinuation of Tirzepatide Therapy

Overview

This report discusses the post hoc analysis of the SURMOUNT-4 trial, highlighting the significant weight regain and reversal of metabolic benefits following the cessation of tirzepatide therapy. The findings emphasize the need for long-term management strategies in obesity treatment.

Background

Obesity is recognized as a chronic condition that often requires ongoing management, particularly when pharmacotherapy is involved. The discontinuation of weight management medications like tirzepatide can lead to rapid weight regain, raising concerns about the sustainability of weight loss and associated metabolic improvements. Understanding the physiological and behavioral factors influencing weight rebound is crucial for developing effective long-term treatment strategies.

Data Highlights

No numerical data available in the source material.

Key Findings

• Weight regain following tirzepatide withdrawal is influenced by physiological counter-regulation, including changes in leptin and ghrelin levels.
• The 36-week lead-in period may not be sufficient to establish lasting lifestyle changes or metabolic memory.
• Absence of body composition data limits understanding of the metabolic consequences of weight regain.
• Future research should focus on hormonal profiling and behavioral support during treatment cessation.
• Continued pharmacotherapy is suggested to maintain weight loss and metabolic benefits.

Clinical Implications

Clinicians should be aware of the high likelihood of weight regain after discontinuation of tirzepatide and consider strategies for long-term management. Monitoring hormonal changes and promoting adherence to lifestyle modifications during treatment cessation may be essential for preventing rebound weight gain.

Conclusion

The findings from the SURMOUNT-4 trial underscore the complexities of managing obesity and the importance of sustained treatment approaches to maintain weight loss and metabolic health.

Related Resources & Content

1. Horn et al, JAMA, 2024 -- Exploring Weight Rebound Following Discontinuation of Tirzepatide Therapy
2. conexiant — Weight Regain Rapidly Follows GLP-1 Cessation
3. conexiant — Tirzepatide Linked to Greater QoL Gains vs Dulaglutide
4. the new gastroenterologist — Tirzepatide outperforms semaglutide for weight loss
5. The New Gastroenterologist — Comparative Gastrointestinal Risk of GLP-1 Receptor Agonists and Tirzepatide
6. Weight Regain Rapidly Follows GLP-1 Cessation
7. Tirzepatide Linked to Greater QoL Gains vs Dulaglutide
8. Tirzepatide outperforms semaglutide for weight loss
9. Current Guidelines on Obesity Management
10. World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network
11. Endocrine Practice 31 (2025) 1351—1394
12. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update - PMC
13. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial | Cardiology | JAMA | JAMA Network
14. Research JAMA Internal Medicine | Original Investi
15. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults | Nature Medicine